Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    GLP, GCP, FDA GXP 2014 - Adverse Event Reporting Compliance; The Key to Safe Drug Development / Subject Safety

    View: 420

    Website http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500242?expDate=Ourglocal | Want to Edit it Edit Freely

    Category seminar; webinar; health; medical; pharma; clinical; drug;

    Deadline: April 23, 2014 | Date: April 23, 2014

    Venue/Country: 38868 Salmon Ter, Fremont California 94536, USA, U.S.A

    Updated: 2014-03-13 23:05:40 (GMT+9)

    Call For Papers - CFP

    By: Dr Charles H Pierce

    Description:

    The principal objective in a new drug development program is to assess the benefit / risk ratio. Learn what the risk information is that must be collected, documented and reported accurately. Learn why the single most important function of the Principal Investigator and the study conduct team is the awareness, assessment, and management of Adverse Events occurring during the conduct of clinical research with drugs or devices utilizing human subjects.

    AE’s are one of the key ways the Clinical Investigator has of monitoring the safety of subjects or patients in her/his charge. To obtain 'commonality' in reporting, investigative sites require familiarity with one of the Adverse Event Terminology systems. As codified in 21 CFR 312.64(b), an investigator shall promptly report to the sponsor any adverse event that may reasonably be regarded as caused by, or probably caused by, the drug.

    See Why determining the relationship between the study drug and an AE requires a practiced power of observation & great care (good medical judgment).

    Without a doubt or question, accurate collecting and reporting of Adverse Events (AE’s) is really the single most important function of the Investigational team as far as Subject safety is concerned.

    Why Should you Attend:

    With the increasing complexity of the Investigational Medicinal Products (IMP’s), it behooves all who have any role in observing Study Participants to know the importance of accurately collecting all AE and SAE data.

    Objectives of the Presentation:

    The definitions of Adverse Events, Serious Adverse Events, Unanticipated Adverse Device Effects and many more

    How to know what an Adverse Event is and when to report it or them

    Knowing the AE types and likelihood of finding “rare” events

    Understanding laboratory AEs and the "Reference Range" concept

    Common Mistakes in AE / SAE Reporting

    Reporting of Adverse Events - when and to whom and the use of AE Terminology systems

    How to record Adverse Events and assess causality - the algorithm

    Who can Benefit:

    This Webinar will provide invaluable assistance to investigators and their staff in the regulatory / legal responsibilities and also the ethical considerations in pharmaceutical product (Drug or device) research involving human subjects. Those benefiting the most would be:

    Principal Investigators

    Sub Investigators

    Clinical Research Scientists (PKs, Biostatisticians, ...)

    Safety Nurses

    Clinical Research Associates (CRAs)

    Clinical Research Coordinators (CRCs)

    QA / QC auditors and staff

    Clinical Research Data managers

    Cheers,

    OnlineCompliancePanel

    http://www.onlinecompliancepanel.com/ecommerce/webinar/~product_id=500242?expDate=Ourglocal


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.